Psychedelics Archives - InvestorWire (IW)

Monday Mar 13, 2023 - 10:30 am

Silo Pharma Inc. (NASDAQ: SILO) Set to Benefit as Study Supports the Efficacy of Psychedelics in Treating ‘Drug-Resistant’ Depression

A recent medical study found that psychedelic drugs showed promise as a treatment alternative for hard-to-treat depression Psychedelics were found to activate a greater number of serotonin 2A receptors then traditional antidepressant drugs, largely because of their ability to penetrated through cells’ fatty outer membranes The study reinforces the potential use of psychedelic drugs, and psilocybin in particular, as a treatment methodology for a variety…

Wednesday Feb 22, 2023 - 9:45 am

Silo Pharma Inc. (NASDAQ: SILO) Granted US Patent For SPC-15 to Prevent and Treat Stress-Induced Disorders

SILO issued US Patent by USPTO titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders In Females” Claims allowed by patent protect use of SPC-15 for treating stress-induced affective disorders, including anxiety and PTSD Other therapeutics in company pipeline include SPU-16 to treat multiple sclerosis, SPU-21 to treat rheumatoid arthritis, SPC-14 to treat Alzheimer’s disease Therapeutics developed by SILO may qualify for FDA’s streamlined 505(b)(2) regulatory drug…

Thursday Jan 26, 2023 - 9:00 am

Silo Pharma Inc. (NASDAQ: SILO) Provides Update on UCSF Psylocibin Clinical

SILO recently provided status update on its sponsored clinical trial with UCSF examining psilocybin’s effects on inflammation Targeted patient populations from study may provide support for development and use of psilocybin as a therapeutic to treat inflammatory conditions Data collection from all study groups expected by April 2023 SILO additionally evaluating its ketamine formulation through its partnership agreement with Zylö Therapeutics Silo Pharma (NASDAQ: SILO),…

Thursday Jan 12, 2023 - 9:00 am

Silo Pharma Inc. (NASDAQ: SILO) Provides Positive Update on Ongoing Study into the Use of Joint Homing Peptides as an Alternative Treatment for Rheumatoid Arthritis

Silo Pharma recently provided an update on an ongoing study delving into the potential use of SPU-21 joint homing peptides as an alternative treatment for rheumatoid arthritis The study, which is being carried out in conjunction with the University of Maryland, Baltimore, has resulted in positive initial results Since its founding, Silo Pharma has rapidly gained a reputation for its innovative approach towards seeking solutions…

Friday Nov 04, 2022 - 9:45 am

Silo Pharma Inc. (NASDAQ: SILO) Extends Columbia University Agreement to Continue Research for Therapeutics to Treat Alzheimer’s Disease

Silo recently extended Columbia University agreement to continue research for novel therapeutics to treat Alzheimer’s disease and stress-induced anxiety disorderPreclinical studies demonstrate Silo’s jointly-developed Z-pod(TM) delivery technology holds and distributes therapeutics in a time-released manner to potentially provide targeted deliveryAdditional treatment research includes funding for the UCSF Translational Psychedelic Program to study effects of psilocybin on various inflammatory conditions Silo Pharma (NASDAQ: SILO), a developmental…

Wednesday Oct 05, 2022 - 10:30 am

Silo Pharma Inc. (NASDAQ: SILO) Successfully Uplists, Commences Trading on the Nasdaq Market

Silo Pharma, Inc recently uplisted to the Nasdaq Capital Market, raising gross proceeds of $5 millionThe biopharmaceutical company has sought to merge traditional therapeutics and psychedelic research, entering into a series of joint ventures with leading medical universities to carry out research into the fieldMeanwhile, psychedelics are gaining increasing favour within the United States with Oregon set to begin allowing the supervised usage of psilocybin…

Tuesday Sep 20, 2022 - 12:00 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Clinical Trial Marks ‘Tremendous’ Milestone as First Participants Receive Initial CYB003 Dose

First dose is administered as first-ever novel psilocybin analog enters clinical developmentCybin believes CYB003 has potential to successfully address the challenges and limitations of oral psilocybinThe high level of participant interest in the study indicates a significant unmet need for alternative treatment options for major depressive disorder (“MDD”) Cybin (NEO: CYBN) (NYSE American: CYBN) has reached a milestone in its mission to create safe and effective…

Wednesday Aug 31, 2022 - 11:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Pioneering Efforts as Studies, Research Show Psilocybin’s Potential in Treating AUD

A new study shows promise in treating alcohol addiction with psychedelic mushroom compound, psilocybinThese results align with efforts and expectations of Cybin, a leading ethical biopharmaceutical company championing psilocybinAfter receiving FDA approval, the company is moving forward with a first-in-human clinical trial evaluating CYB003 A new study published in JAMA Psychiatry offers hope for those struggling with alcoholism (https://ibn.fm/jV5o9), showing promise in treating alcohol addiction…

Friday Aug 26, 2022 - 9:45 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leading Out in Transformation of Psychedelic Sector

Psilocybin is seeing a “research resurgence” focused on how the substance changes the brain's connectivity patternsCYBN is leading the industry in developing proprietary psychedelic-based therapeuticsThe company’s lead investigational molecule has the potential to treat major depressive disorder and alcohol use disorder The status of psilocybin is evolving as a result of mounting public acceptance and growing evidence that the substance delivers remarkable health benefits. Cybin…

Wednesday Aug 17, 2022 - 9:30 am

Silo Pharma Inc. (SILO): Promising Psylocibin Study Ongoing with UCSF

Company entered scientific research agreement with UCSF in June 2021 to study psilocybin effects on various inflammatory conditions Silo Pharma (OTCQB: SILO), recently announced that the University of California San Francisco (“UCSF”) had successfully administered psilocybin to a test group of Parkinson’s disease patients as part of a scientific research agreement (“SRA”) entered with Silo in June, 2021 to “to determine the effects of psilocybin…

Wednesday Aug 03, 2022 - 12:00 pm

Silo Pharma Inc.’s (SILO) Ketamine Study Produces Positive Endpoint Results, Suggests Topical Formulation Reduces Neuropathic Nerve Pain

Silo recently completed ketamine study showing neuropathic nerve pain reduction when administered with patented, partnered delivery systemResults of study demonstrated Silo’s topical ketamine formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points, mechanical hyperalgesia reduced on day seven at the pre-dose time pointKetamine typically used to induce and maintain anesthesia, drug use expanding to include depression and chronic pain treatment at…

Thursday Jul 28, 2022 - 10:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Cleared for Historic Study, Begins Enrolling Participants

Company receives FDA “may proceed” letter and investigational new drug (“IND”) application clearanceEnrollment for Phase 1/2a trial has already startedUpcoming trial is first time a psilocybin analog will be evaluated for MDD treatmentStudies show psychedelic-based treatments may have potential to revolutionize mental healthcare, but few companies have assessed limitations of oral psilocybin In a first-ever milestone, Cybin (NEO: CYBN) (NYSE American: CYBN) received approval from the…

Monday Jul 25, 2022 - 11:15 am

Silo Pharma Inc. (SILO) Produced Initial Liposome Batch for Rheumatoid Arthritis Study

Silo Pharma produced initial batch of SPU-21 liposomes for rheumatoid arthritis study conducted by CRO Frontage LaboratoriesRecent company research revealed SPU-21 liposomes can target inflamed epithelium, suggesting use for targeted drug deliverySPU-21 can be used for development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis Company recently announced positive results in subcutaneous delivery of novel liposomes vs. intravenous injection Silo Pharma (OTCQB: SILO), a…

Monday Jul 25, 2022 - 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Completes Acquisition of Largest-Ever DMT Study

Data from newly acquired study could accelerate clinical development of CYBN’s CYB004 by nine monthsThe pivotal study was designed with four primary objectivesCybin’s proprietary substance has potential to effectively treat anxiety disorders, including GAD and SAD Cybin (NEO: CYBN) (NYSE American: CYBN) has completed the acquisition of the largest dimethyltryptamine (“DMT”) study to date, a Phase 1 N,N-DMT study that provides key data relating to the…

Wednesday Jul 13, 2022 - 9:00 am

Homing Peptides: Silo Pharma Inc. (SILO) Targets ADRs

Silo’s partnership with UMB could yield therapeutics that limit side effects through precisely targeted delivery On February 3, 2022, Silo Pharma (OTCQB: SILO) extended its research partnership with the University of Maryland, Baltimore (“UMB”) to explore potentially lifesaving joint-homing peptides that target inflamed endothelium (a thin membrane that lines the inside of the heart and blood vessels). The ability to target inflamed tissue (while bypassing…

Monday Jun 27, 2022 - 2:15 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Initial Results from Feasibility Study

Study indicates that ketamine-induced changes in functional connectivity last for several days after administration of the substanceKernel Flow gathers real-time functional brain activity during clinical and research studies evaluating psychedelic-based therapeuticsTechnology is “precisely what we need to accelerate the development of psychedelics into therapeutics,” says Cybin CEO New data confirms Cybin’s (NEO: CYBN) (NYSE American: CYBN) focus on and commitment to progressing psychedelics to therapeutics. The…

Monday Jun 27, 2022 - 1:30 pm

Silo Pharma Inc. (SILO) Takes Aim at Alzheimer’s Disease

In October 2021, Silo Pharma (OTCQB: SILO) entered into a sponsored research agreement (“SRA”) with Columbia University to investigate and advance psychedelic therapeutics for Alzheimer's Disease (“AD”). SRA’s grant Silo access to world-class research facilities to sponsor potential life-changing research while offering Silo licensing opportunities for groundbreaking psychedelic remedies. Columbia University Irving Medical Center (“CUIMC”), an “internationally recognized leader” in research and therapeutic development, partnered…

Tuesday May 31, 2022 - 11:15 am

Silo Pharma Inc. (SILO) Focuses on Psilocybin’s Anti-Inflammatory Properties

On May 19, 2022, Silo Pharma (OTCQB: SILO) announced that The Translational Psychedelic Research (“TrPR”) Program at UCSF (University of California San Francisco) had “successfully dosed [with psilocybin] patients suffering from Parkinson’s disease.” TrPR connects researchers and medical professionals studying how psychedelics, including psilocybin, ketamine, etc., affect brain functions and other organ systems. Silo Pharma focuses on palliative uses of psychedelics for “PTSD, Parkinson’s, and…

Tuesday May 31, 2022 - 9:45 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) and Kernel Report Result of Study Measuring Ketamine’s Effects on the Brain

Study shows that COVID-19 pandemic has affected mental health of 59% of U.S. population, intensifying already-serious issueCYBN-sponsored feasibility study indicates ketamine-induced changes in brain’s functional connectivity persisted for several days after receiving the substanceKernel Flow pivotal in developing most accurate, effective treatment regimens for patients The challenges associated with mental-health issues are rising, following the global pandemic. Already a serious problem before COVID-19, mental health…

Thursday May 26, 2022 - 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Efforts Boosted by New Study Indicating Effectiveness of Psychedelic Compounds

Recent study indicates psychedelic compounds show significant promise in treating a range of mental-health disordersParticipants given psilocybin therapy reported a rapid, sustained improvement in their depressionCybin’s CYB003 has demonstrated less variability, faster onset, shorter duration and better brain penetration than oral psilocybin A new study sponsored by Imperial College London reports that psychedelic compounds may be effective in treating mental-health disorders (https://ibn.fm/xSdZv). The study supports…

Thursday May 19, 2022 - 9:00 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Adds Neuro-enhancing Therapies to 6 KWC Clinics, With Plans to Expand Across the Nation

Delic Holdings Corp works to develop novel solutions for hard-to-treat mental and emotional disordersThe company’s Ketamine Wellness Centers (“KWC”) clinical subsidiary recently announced the addition of NAD+ (nicotinamide adenine dinucleotide) infusion therapies as a means of boosting natural energy stores and immunity, brain and DNA function, and cell communicationThe NAD+ therapies will launch in six of KWC’s clinics on May 9 — in Jacksonville, Fla.;…

Tuesday May 17, 2022 - 9:45 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Capitalizing on Psychedelics Drug Market, with 13 Wellness Clinics Across Nine States and Growing

Delic Holdings Corp. comprises several businesses—Delic Labs, Meet Delic, and Ketamine Wellness Centers and media properties Reality Sandwich and Delic Radio The psychedelic drugs market is expected to reach US $9,818.68 million by 2029 – primarily driven by an increase in acceptance for use in mental healthThe company’s goal is to expand its clinic offering to 60-70% of the American population driving no more than 45-minutes…

Wednesday May 11, 2022 - 11:15 am

Silo Pharma Inc. (SILO) Spotlight: Ketamine

Ketamine shows promise in treating Alzheimer’s Disease, Parkinson’s Disease as well as depression, suicide ideation and more In 2021, Silo Pharma (OTCQB: SILO) entered into a joint venture with Zylö Therapeutics to “explore the clinical development of ketamine using ZTI’s Z-pod (transdermal) technology.” This innovative technology allows Silo, an early-stage biopharmaceutical company, to develop a ketamine delivery system for those suffering dysphagia, a difficulty or…

Friday May 06, 2022 - 9:00 am

Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Proprietary CYB003 Set to Move Forward in First-in-Human Phase 1/2a Clinical Trial

Cybin has selected Clinilabs Drug Development Corporation as CRO for its Phase 1/2a clinical trial evaluating CYB003 for treating major depressive disorder (“MDD”)MDD impacts more than 264 million people worldwide, is a leading cause of mental disability worldwidePreclinical studies show CYB003 may have significant advantages over classic psilocybin In a significant step forward in the study of alternative treatments for major depressive disorder, Cybin (NEO:…

Tuesday May 03, 2022 - 9:00 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Set to Present Update on its Psychedelic Wellness Ecosystem at Las Vegas MicroCap Event

Delic Holdings Corp was founded four years ago, devoted to making psychedelic drug therapies available to patients with hard-to-treat mental and emotional conditions The company’s research arm has received authorization in Canada to work with substances such as psilocybin, MDMA (Ecstasy), LSD, DMT (Dimitri), mescaline and 2C-BIn the United States, the company operates the country’s largest chain of ketamine (anesthesia-related medication) clinics for wellness therapiesDelic Co-founder…

Friday Apr 29, 2022 - 9:00 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Driving the Psychedelic Conversation Forward Through Education, Research, and Service Delivery

Delic is committed to bringing science-backed benefits to as many people as possible while also changing the narrative around psychedelicsIt seeks to achieve this through education, products and services, and research on psychedelics So far, LSD and psilocybin have proven to reduce end of life (“EOL”) anxiety for terminally ill patientsDelic recognizes the potential of psychedelics and their application in therapeutics, hence its investment in research,…

Thursday Apr 28, 2022 - 9:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Preclinical Data from CYB004 Study Showing Significant Advantages

Earlier studies show that CYB004 via inhalation may solve existing challenges and support a clinical path forward for this important therapeuticCybin is currently developing CYB004 for the treatment of anxiety disordersThe new chemical entity is covered by a patent issued earlier this year Cybin (NEO: CYBN) (NYSE American: CYBN) has released data from a pharmacokinetic study focused on evaluating CYB004, the company’s proprietary deuterated dimethyltryptamine (“DMT”)…

Wednesday Apr 27, 2022 - 9:00 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Moves to Become the Go-To Provider of Psychedelic Medicine Treatment as it Seeks Approval of Additional Compounds

Delic is a leader in new medicines and treatments that offers education, research, high-quality products, and treatment optionsThe company is on a mission to help heal the mental health pandemic, which has been triggered and worsened by the COVID-19 diseaseDelic operates the largest, most profitable chain of wellness clinics providing ketamine treatments in the United StatesWith 13 clinics already in operation, Delic is eyeing expansion…

Wednesday Apr 20, 2022 - 9:15 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Achieves Key Milestone in the Advancement of Its Research Efforts

Delic Labs just received its Health Canada 56 Research Exemption, enabling it to develop innovative analytical methods for psychedelic researchThe company first applied for the exemption in October 2021, along with a Dealer’s License for commercializing psilocybin research and associated IP for medical and research purposesWith this significant milestone, Delic Labs is leading the way in psychedelic compound testing and ensuring the safety and effectiveness…

Monday Apr 18, 2022 - 9:30 am

Mullen Automotive Inc. (NASDAQ: MULN) Named EV Startup to ‘Watch Out For’ by Leading Auto Site

Mullen called “dark horse” in HotCars 2022 list of top EV startupsOther online articles also shining spotlight on what CarBuzz calls “the real deal” Mullen CEO calls FIVE model “just the start” Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, is starting the new year with a bang: the company is ranked no. 2 on the HotCars 2022 list of top-10 EV startups (https://ibn.fm/Gb5IR).…

Monday Apr 18, 2022 - 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CYB004 Pipeline Program Receives Key Patent Approval from WIPO

World Intellectual Property Organization has published CYBN’s international patent applicationPublication of patent application demonstrates CYBN’s continued commitment to discovering, developing psychedelic-based treatment optionsCompany continues to see strong protection for growing intellectual property portfolio of psychedelic-based compounds Cybin (NEO: CYBN) (NYSE American: CYBN) announced that the World Intellectual Property Organization (“WIPO”) has published an international patent application filed by Cybin. According to Cybin, the application, titled "Methods…

Wednesday Apr 13, 2022 - 9:30 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Introduces FDA-Approved SPRAVATO(R) Nasal Spray at KWC Clinics in a Move to Make Mental health Treatment Effective and Affordable

Ketamine Wellness Centers (“KWC”), a subsidiary of Delic Holdings, just expanded its treatment options to include SPRAVATO(R) nasal spray beginning April 1SPRAVATO received FDA approval back in 2019 and would be used in conjunction with an oral antidepressantIts introduction to KWC clinics underscores the company’s commitment to providing clinically-backed, accessible and affordable treatments to patients nationwide Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), through…

Tuesday Apr 12, 2022 - 9:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Provides Business Update, Marking 2021 Achievements

In 2021, Mydecine made significant progress in creating and commercializing new treatments for mental health and addiction disordersIt also made a noteworthy shift in focus to reducing expenses and increasing efficiencies for continued clinical trials and the expansion of its IP portfolioFor 2022, the company plans to build on the progress achieved in 2021With new additions to its board, its conditional IRB approval, and the…

Monday Apr 11, 2022 - 9:00 am

Silo Pharma Inc. (SILO) Emerging Leader as Psychedelics ‘on the Cusp of Entering Mainstream Psychiatry’

Mainstream acceptance of psychedelics took a “significant leap forward” with study results published in “Nature Medicine”Many say it is only a matter of time before FDA grants approval for psychoactive compounds to be used therapeuticallySILO is focused on merging traditional therapeutics with psychedelic research for people suffering from underserved indications “The Psychedelic Revolution Is Coming,” proclaims a “New York Times” article, which notes that as…

Friday Apr 08, 2022 - 9:15 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Strengthening Foothold in Multibillion-Dollar Mental Health Space

Recent study forecasts global mental health market to reach almost $538B by 2030One in five people in the United States deals with mental illness, including depression, anxiety, PTSD and moreCybin is moving three drug candidates forward, targeting major depressive, alcohol use and anxiety disorders A recent market study reports that the global mental health market, which was valued at $383.31 billion in 2020, is estimated…

Tuesday Apr 05, 2022 - 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Begins Recruitment for Study Measuring Ketamine’s Psychedelic Effect

Cybin-sponsored study will use Kernel Flow, Kernel’s quantitative neuroimaging.Company hopes to learn more about impact ketamine has on brain activity, overall mental well-being.Study results may lead to future studies supporting CYBN’s mission to develop psychedelics into therapeutics. Cybin’s (NEO: CYBN) (NYSE American: CYBN) efforts to transform the mental-health treatment landscape have reached a key milestone: the company is actively recruiting participants for its upcoming feasibility study…

Tuesday Apr 05, 2022 - 9:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Leveraging Growth Across Multiple Markets Including Mental Health, Healthcare IT

Mydecine was founded in 2020 as a response to the lack of innovation addressing mental health treatment and the therapeutic possibilities represented by psychedelic compounds and other novel moleculesThe world is experiencing a shortage of mental health resources, while faced with an increase in mental health issues on the heels of the pandemicMydecine is leveraging the psychedelic drugs market, the PTSD market, and healthcare IT…

Monday Apr 04, 2022 - 9:15 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) CEO to Present at Three Upcoming Investor Conferences Spotlighting the Company’s Strategic Outlook for the Remainder of 2022

Delic Holdings Co-founder and CEO, Matt Stang, will take part in three upcoming conferences – the Scottdale Capital Event, the Planet MicroCap Showcase, and the H.C. Wainwright Annual Global Life Sciences ConferenceIn presentations and one-on-one meetings, Stang will discuss Delic’s new revenue lines and strategic outlook for the remainder of the yearDuring a recent interview on The Jesse Tee Show, Stang noted the company intends…

Monday Mar 28, 2022 - 9:00 am

Psychedelic Medicine Researcher Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Readies IND Application to Advance Drug Trials

Novel drug development company Mydecine Innovations Group is focusing on a medicinal pipeline for psychedelic drug candidates that have established some efficacy in treating mental illnesses — specifically addictionMydecine is progressing in its clinical trial evaluation of its lead candidate, MYCO-001, and is finalizing an IND application with the FDA to begin patient dosing for its planned Phase 2 trialsThe company is targeting nicotine addiction…

Friday Mar 25, 2022 - 9:00 am

Delic Holdings Corp (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Makes Psychedelic Treatment More Accessible with Opening of New Reno Clinic

Following the acquisition of KWC back in November 2021, Delic Holdings Corp set out to open additional state-of-the-art ketamine infusion treatment clinics over the course of 18 monthsThe company has just announced the opening of its second clinic in Nevada in a move that will serve both local patients and those in larger California markets without access to affordable in-state providersDelic is still set to…

Articles

Articles Category: Psychedelics

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions